17587-95-0

Basic information

• Product Name: 2-chloro-N4-methylpyrimidine-4,5-diamine
• Synonyms: 2-chloro-N4-methylpyrimidine-4,5-diamine;AKOS A0602-0613;2-chloro-N4-methyl-4,5-Pyrimidinediamine;2-chloro-4-N-methylpyrimidine-4,5-diamine
• CAS NO: 17587-95-0
• Molecular Formula: C₅H₇ClN₄
• Molecular Weight: 158.59
• Mol File: 17587-95-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 387.4 °C at 760 mmHg
• Flash Point: 188.1 °C
• Appearance: /
• Density: 1.447 g/cm³
• Vapor Pressure: 3.31E-06mmHg at 25°C
• Refractive Index: 1.675
• CAS DataBase Reference: 2-chloro-N4-methylpyrimidine-4,5-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-N4-methylpyrimidine-4,5-diamine(17587-95-0)
• EPA Substance Registry System: 2-chloro-N4-methylpyrimidine-4,5-diamine(17587-95-0)

Safety Data

• Hazardous Substances Data: 17587-95-0(Hazardous Substances Data)

Usage

General Description

2-chloro-N4-methylpyrimidine-4,5-diamine is a chemical compound with the molecular formula C5H7ClN4. It is a derivative of pyrimidine and is used in the synthesis of various pharmaceuticals and agricultural chemicals. 2-chloro-N4-methylpyrimidine-4,5-diamine is a potent inhibitor of dihydrofolate reductase, an enzyme that is essential for the synthesis of DNA and cell division. It has also been studied for its potential use in antimalarial drugs and as a pesticide. 2-chloro-N4-methylpyrimidine-4,5-diamine is an important chemical reagent in the development of various therapeutic and agricultural products.

InChI:InChI=1/C5H7ClN4/c1-8-4-3(7)2-9-5(6)10-4/h2H,7H2,1H3,(H,8,9,10)

Upstream product

• 2273-93-0 2,6-dichloro-7-methylpurine 
• 89283-49-8 2-chloro-4-(methylamino)-5-nitropyrimidine 

Downstream Products

• 1273307-62-2 2-(2-methoxyethyl)-9-methyl-7-({3-[4-(trifluoromethyl)phenyl]azetidin-1-yl}carbonyl)-7,9-dihydro-8H-purine-8-one hydrochloric acid salt 
• 1273388-39-8 2-(3-methoxypropyl)-9-methyl-7-({3-[4-(trifluoromethyl)phenyl]azetidin-1-yl}carbonyl)-7,9-dihydro-8H-purine-8-one 
• 1273315-11-9 2-chloro-9-methyl-7H-purin-8(9H)-one 
• 1273315-68-6 2-cyclohexyl-9-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7,9-dihydro-8H-purine-8-one 
• 1273315-70-0 2-cyclohexyl-9-methyl-7,9-dihydro-8H-purine-8-one 
• 1273315-37-9 9-methyl-2-(2-phenylethyl)-7,9-dihydro-8H-purine-8-one 
• 1273315-21-1 9-methyl-2-[(E)-2-phenylethenyl]-7,9-dihydro-8H-purine-8-one 
• 1273304-67-8 2-benzyl-9-methyl-7-(pyrrolidin-1-ylcarbonyl)-7,9-dihydro-8H-purine-8-one 
• 1273302-07-0 2-(2-fluorophenyl)-9-methyl-7-(pyrrolidin-1-ylcarbonyl)-7,9-dihydro-8H-purine-8-one 
• 1273298-36-4 9-methyl-2-[(E)-2-phenylethenyl]-7-(pyrrolidin-1-ylcarbonyl)-7,9-dihydro-8H-purine-8-one 
• 872856-32-1 N-[4-methyl-3-(2-chloro-8-methyl-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-trifluoromethyl-benzamide 

Relevant articles and documents

FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I) where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.

8-OXODIHYDROPURINE DERIVATIVE

The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one of X and Y represents a di-substituted alkylaminocarbonyl group, or the others, and the other represents a hydrogen atom, an alkyl group, an alkylcarbonyl group, or the others); a medicament or a pharmaceutical composition for treatment or prophylaxis of FAAH-related diseases such as depression, anxiety disorder or pains, comprising the compound or the like as an active ingredient; a use of the compound or the like; and a method for treatment or prophylaxis using the compound or the like.